Does lurbinectedin cause adverse effects with other drugs?
Yes, lurbinectedin (brand name Zepzelca) has known drug interactions that can increase adverse effects. It is metabolized by CYP3A enzymes and inhibits P-glycoprotein (P-gp), leading to higher risks of toxicity when combined with certain medications. Common issues include elevated myelosuppression (low blood cell counts), nausea, fatigue, and liver enzyme increases.[1]
What are the main interacting drug classes?
- Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin): Raise lurbinectedin levels, worsening neutropenia, thrombocytopenia, and anemia. Avoid or reduce lurbinectedin dose by 25-33%.
- Strong CYP3A inducers (e.g., rifampin, carbamazepine, St. John's wort): Lower lurbinectedin exposure, potentially reducing efficacy; avoid use.
- P-gp substrates (e.g., digoxin, dabigatran): Lurbinectedin may increase their levels, raising toxicity risks like bleeding or arrhythmias. Monitor closely or adjust doses.
- Other chemotherapy agents: Combinations like doxorubicin or cisplatin amplify bone marrow suppression and gastrointestinal effects, as seen in small cell lung cancer trials.[1][2]
No major interactions reported with irinotecan or topotecan, but additive cytopenias can occur.
How does it interact with common supportive medications?
Lurbinectedin often pairs with dexamethasone (for antiemetic prophylaxis), which has no significant interaction. Avoid concurrent use with live vaccines due to immunosuppression risk. Proton pump inhibitors (e.g., omeprazole) may slightly reduce absorption; monitor response.[1]
What monitoring is needed during combination therapy?
Check CBC weekly for cytopenias, liver function tests before each cycle, and ECG for QT prolongation risks with certain QT-prolonging drugs (e.g., ondansetron). Dose delays or reductions are common (75% of patients in trials).[2]
Are there patient-specific risks or alternatives?
Elderly patients or those with liver impairment face higher toxicity from interactions. Alternatives like topotecan have fewer CYP3A issues but similar myelosuppression. Consult prescribing info for full list; no dedicated interaction database flags unique patents affecting combos.[1][3]
[1]: Zepzelca (lurbinectedin) prescribing information, Jazz Pharmaceuticals, https://www.zepzelca.com/
[2]: FDA label and approval summary for lurbinectedin, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf
[3]: DrugPatentWatch.com entry for lurbinectedin, https://www.drugpatentwatch.com/p/tradename/ZEPZELCA